结直肠癌患者外周血中癌胚抗原-mRNA的表达及其临床意义

目的：肿瘤复发转移仍是威胁患者生存的重要原因，及早检出外周血中的循环肿瘤细胞并进行有效的综合治疗有着重要的临床意义。检测结“直肠癌患者外周血中癌胚抗原（CEA）－mRNA的表达及血清CEA蛋白的含量，并分析其临床价值。方法：35例有明确临床肿瘤病灶存在的结直肠癌患者、9例根治术后患者和37例健康志愿者，分别以逆转录PCR（RT－PCR）检测其外周血中CEA－mRNA的表达，时间分辨荧光方法测定其血清CEA蛋白的含量。结果：35例结直肠癌患者CEA－mRNA阳性率为45．7％，而健康对照组阳性率为2．7％，两者比较差异有显著性（P＜0．05）；9例术后患者CEA－mRNA仅2例阳性；CEA－mRNA阳性表达率与肿瘤分期相关，与肿瘤细胞分化程度并不相关。CEA－mRNA阳性组血清CEA蛋白阳性率（72．2％）显著高于CEA－mRNA阴性组（42．3％）。结论：外周血细胞中CEA－mRNA的表达与肿瘤分期相关，有可能作为结直肠癌微转换的一个监测指标。长期的随访有助于评价其临床价值。     

CCL2表达与同时性结直肠癌肝转移的相关性分析

目的观察结直肠癌原发瘤CCL2表达与同时性结直肠癌肝转移的相关性。 方法检索1999年1月至2003年12月中国医学科学院肿瘤医院临床病理资料完整的结直肠癌病例,最终197例纳入研究。其中对照组104例,同时性肝转移组93例。对照病例定义为结直肠癌术后随访5年以上没有复发转移者。采用免疫组织化学法检测结直肠癌原发瘤CCL2表达,单因素和多因素分析CCL2和临床病理因素与结直肠癌肝转移的相关性。 结果多因素分析显示,肿瘤大小、淋巴结分期、CEA和CCL2表达是预示结直肠癌肝转移的独立危险因素(P<0.05),CCL2高表达者肝转移风险是低表达者的5.828倍(95% CI：2.212～15.355)。CCL2与其他临床病理因素的相关性分析表明,CCL2表达仅与肝转移相关(P<0.05),与肿瘤浸润深度、淋巴结分期和CEA均未见统计学差异(P>0.05)。 结论同时性结直肠癌肝转移与肿瘤大小、淋巴结分期、CEA和CCL2表达密切相关。结直肠癌肝转移中CCL2的作用机制可能与常见临床病理因素不同。     

氟脱氧葡萄糖-正电子发射断层成像术在诊治结直肠癌肝转移中的作用

结直肠癌是常见的消化道恶性肿瘤，术后复发率高达50％．常见转移部位为肝脏（40％～50％）、肺（25％～30％）、骨和脑。对于结直肠癌肝转移患者，手术是目前唯一有效的治疗措施．可将5年生存率提高至约40％。以往多采用检测癌胚抗原（CEA）、行B超、CT和结肠镜检查等对结直肠癌术后患者进行随访。如发现孤立性肝转移灶，还需行胸腹部CT检查以判断是否存在肝外病灶和评估手术的可行性。但是，尽管已采取上述一系列措施，仍有不少具手术适应证的患者因在术中发现其他转移灶而终止手术。     

术前血清CEA、CA19-9、CA50联合检测在结直肠癌肝转移预测中的应用

目的研究术前血清CEA、CA19-9、CA50联合检测在结直肠癌肝转移预测中的应用价值。 方法选择2015年1月至2017年1月在中国医学科学院肿瘤医院接受手术治疗的结直肠癌患者316例为研究对象,其中结直肠癌伴有肝转移的患者158例作为实验组,并按照性别、年龄等匹配结直肠癌不伴有肝转移的患者158例作为对照组。对所有患者的术前血清癌胚抗原（CEA）、糖类抗原19-9（CA19-9）以及糖类抗原50（CA50）进行检测,采用单因素及多因素分析以上肿瘤标志物单独或联合检测在结直肠癌肝转移中的预测价值。 结果单因素及多因素分析结果表明,术前血清CEA、CA19-9、CA50升高与结直肠癌发生肝转移显著相关（P<0.05）,CEA、CA19-9、CA50单独预测结直肠癌肝转移的敏感度分别为62.7%、57.4%、67.1%;特异度分别为58.2%、53.5%、56.6%。CEA、CA19-9、CA50联合诊断预测直肠癌肝转移的敏感度和特异度分别为74.3%、76.3%。 结论术前血清CEA、CA19-9、CA50升高是结直肠癌肝转移的独立预测因素,但三者单独预测结直肠癌肝转移的敏感度和特异度均较低。三者联合检测对于预测结直肠癌肝转移的敏感度和特异度均较高,可以作为结直肠癌肝转移的预测模型。     

2009 WCIO肝转移癌研究

1 TACE治疗结直肠癌肝转移疗效评价 德国学者对207例结直肠癌肝转移患者接受肝动脉化疗栓塞治疗（TACE）的效果进行了分析。实体瘤疗效评价标准（RECIST）结果显示，12％部分缓解，51％疾病稳定，37％疾病进展。患者1年生存率为62％，2年生存率为38％。从诊断肝转移起的中位生存期为3．4年，从TACE治疗起的中位生存期为1．34年。     

结直肠癌患者血清Ang-2含量检测及意义

目的探讨结直肠癌患者血清血管生成素-2（Ang-2）含量变化的临床意义。方法采用ELISA法分别检测185例结直肠癌患者、46例结直肠腺瘤息肉患者、33例炎症性肠病患者、65例肠道良性病变患者及30例正常对照者血清Ang-2、癌胚抗原（CEA）含量,并检测结直肠癌患者术后各随访组及肿瘤复发组血清Ang-2、CEA含量,分析血清Ang-2含量与结直肠癌病理特征的关系。结果结直肠癌组及肿瘤复发组Ang-2含量显著高于正常组和肠道良性病变组,结直肠腺瘤息肉组及炎症性肠病组Ang-2含量亦明显高于正常组（P均〈0.05）,而CEA含量无明显升高（P〉0.05）。术后各随访组Ang-2与CEA含量较术前均显著降低（P均〈0.01）。结直肠癌组血清Ang-2含量与肿瘤大小、肿瘤分化程度、病理分期均呈正相关（P〈0.05或0.01）。结论血清Ang-2含量可作为一种新的结直肠癌肿瘤标志物,有助于结直肠癌的临床诊断与评价、术后复发及高危对象的监测。     

贝伐单抗联合化疗治疗进展期转移性结直肠癌临床观察

目的评价贝伐单抗联合IFL方案（伊立替康、氟尿嘧啶、亚叶酸钙）治疗进展期结直肠癌的疗效及安全性。方法回顾性总结2007年6月～2009年8月期间分别给予贝伐单抗联合IFL方案（A组,40例）和单独IFL方案（B组,37例）进行化疗患者治疗后有效率、不良反应、治疗前后肿瘤标志物的变化和随访情况。结果A组和B组的有效率分别为40．0％和21．6％;所有患者治疗前后肿瘤标志物浓度均有明显变化（P〈0．05）,A组和B组比较差异具有统计学意义（P〈0．05）,两组不良反应为Ⅰ～Ⅱ度,无严重不良反应,且差异无统计学意义（P〉0．05）;A组患者1年存活率为27．5％,其中生存期（OS）最长者达15．6个月,中位疾病进展期（TTP）为4．9个月,中位OS为10．5个月。B组患者1年存活率为18．9％,其中OS最长者达12．3个月,中位TTP为3．4个月,中位OS为8．8个月。两组1年存活率、中位TTP、中位OS比较,差异均具有统计学意义（P〈0．05）。结论与单独使用IFL方案相比,贝伐单抗联合化疗对于进展期转移性结直肠癌治疗具有良好的效果,多数患者不良反应为轻到中度,毒副作用发生率低,患者能够耐受,能明显延长患者的生存期。     

肺癌患者外周血癌胚抗原、细胞角蛋白19mRNA表达水平与肿瘤分期、近期疗效及预后的关系

目的探讨肺癌患者治疗前后外周血癌胚抗原（CEA）、细胞角蛋白19（CK19）mRNA的表达水平及其与肿瘤分期、近期疗效、预后的关系。方法应用TaqMan定量逆转录-聚合酶链反应（RT-PCR）检测78例肺癌患者（鳞癌28例、腺癌40例、小细胞肺癌9例、大细胞肺癌1例）治疗前后、30例肺部良性疾病患者及30名健康对照者外周血癌胚抗原（CEA）、细胞角蛋白19（CK19）mRNA的水平；同时采用酶联免疫吸附法测定肺癌患者治疗前血清CEA和细胞角蛋白19片段（CYFRA21-1）水平。患者随访2年。结果肺癌患者外周血CEA、CK19mRNA阳性率分别为69．2％（54／78）、62．8％（49／78），显著高于肺部良性疾病患者及健康对照者，三者差异有统计学意义（χ^2值分别为37．65、41．54；27．41、30．84，P均〈0．01）。鳞癌组CK19mRNA阳性率最高，腺癌组CEAmRNA阳性率最高。不同分期肿瘤患者间CEA、CK19mRNA阳性率差异无统计学意义（χ^2值分别为3．63、3．81，P〉0．05）。肺癌患者外周血CEA、CK19mRNA的阳性率显著高于CEA、CYFRA21-1蛋白水平；手术后CEA、CK19mRNA阳性率显著下降；化疗后阳性率下降不明显。化疗前CEAmRNA阳性患者的中位生存期明显低于阴性患者（分别为8．5、11．7个月），化疗前CK19mRNA阳性患者的中位生存期明显低于阴性患者（分别为8．9、12．3个月）；术前CEAmRNA阳性患者肿瘤复发或转移率（29．4％）高于术前阴性患者（7．7％），术前CK19mRNA阳性患者肿瘤复发或转移率（18．8％）高于术前阴性患者（7．1％）。结论检测肿瘤患者外周血CEA、CK19mRNA水平对于预测肿瘤细胞微转移有一定的临床意义，有助于评估手术疗效及预测预后。CEA、CK19mRNA表达水平与肿瘤分期无关。CEA、CK19基因检测的敏感性优于蛋白水平的检测，有助于肺癌的辅助诊断。     

肝转移癌的介入治疗

肝转移癌在临床上极为常见，在西方国家，肝转移癌和原发性肝癌的比例约为20：1，在我国，两者发生概率相近。肝转移癌源于结、直肠癌者最多见，预后不良，平均生存时间仅6～12个月。按现代肝转移癌的治疗观点，可能治愈肝转移癌的方法主要是外科手术治疗（包括肝移植术），手术后患者平均5年生存率为25％～35％，但近三分之一患者术后出现肿瘤复发。近年来，随着现代医学的蓬勃发展，     

结直肠癌肝转移预后因素分析及治疗方式对生存期的影响

目的研究在原发癌切除术后,结直肠癌肝转移患者的临床特征与预后之间的相关性。方法对118例结直肠癌肝转移患者13个临床病理特征进行单因素生存分析及多因素COX风险回归模型的分析。各种治疗方法对1、3、5 a生存率及中位生存期的影响应用生存寿命表法进行比较。结果手术组的生存期明显长于姑息治疗组和未治疗组。原发癌的TNM分期、术前CEA、肝转移灶的最大径和发现时间、肝外转移的存在以及原发癌切除术后的治疗方式等6个因素对结直肠癌肝转移患者的中位生存期存在显著性影响（P〈0.05）。原发癌的TNM分期、术前CEA、肝转移灶的大小与结直肠癌肝转移长期生存的危险性呈正相关。结论结直肠癌肝转移患者的临床病理特征与患者预后有着密切关系。手术治疗,特别是手术联合全身化疗、肝动脉介入化疗等综合治疗比单纯治疗具有更佳的疗效。     

Percutaneous cryosurgery for the treatment of hepatic colorectal metastases

AIM：To determine the safety and efficacy of efficacy of percutaneous cryosurgery for treatment of patients with hepatic colorectal metastases.
METHODS： Three hundred and twenty-six patients with non-resectable hepatic colorectal metastases underwent percutaneous cryosurgery under the guidance of ultrasound or CT. Follow-up was 1 mo after cryosurgery and then every 4 mo thereafter by assessment of tumor markers, liver ultrasonography, and abdominal CT. For lesions suspicious of recurrence, a liver biopsy was performed and subsequent repeat cryosurgery was given if histology was positive for cancer.
RESULTS： All patients underwent a total of 526 procedures of cryosurgery. There were 151 patients who underwent repeat procedures of cryosurgery for recurrent tumors in the liver and extrahepatic places. At 3 mo after cryosurgery, carcinoembryonic antigen （CEA） levels in 197 （77.5%） patients who had elevated markers before cryosurgery decreased to normal range. Among 280 patients who received CT following-up, cryotreated lesions showed complete response （CR） in 41 patients （14.6%）, partial response （PR） in 115 patients （41.1%）, stable disease （SD） in 68 patients （24.3%） and progressive disease （PD） in 56 patients （20%）. The recurrence rate was 47.2% during a median follow-up of 32 mo （range, 7-61）. Sixty one percent of the recurrences were seen in liver only and 13.9% in liver and extrahepatic areas. The recurrence rate at cryotreated site was only 6.4% for all cases. During a median follow-up of 36 mo （7-62 mo）, the median survival of all patient was 29 mo （range 3-62 mo）. Overall survival was 78%, 62%, 41%, 34% and 23% at 1, 2, 3, 4 and 5 years, respectively, after the treatment. Patients with tumor size less than 3 cm, tumor in right lobe of liver, lower CEA levels （〈 100 ng/dL） and post- cryosurgery TACE had higher survival rate. There wasno significant difference in terms of survival based on the number of tumors, pre-cryosurgery chemotherapy and t     

Cryosurgery with combination of (125)iodine seed implantation for the treatment of locally advanced pancreatic cancer

OBJECTIVE: To study the therapeutic value of cryosurgery with combination of (125)iodine seed implantation for locally advanced pancreatic cancer. METHODS: Thirty-eight patients with locally advanced pancreatic cancer were enrolled in this study. The diagnosis was confirmed by pathology in 31 patients. Ten patients had metastases of the peripancreatic lymph node and eight had liver metastases. The therapy included cryosurgery, which was performed intra-operatively or percutaneously under guidance of ultrasound and/or computed tomography (CT), and (125)iodine seed implantation, which was performed during cryosurgery process or post-cryosurgery under the guidance of ultrasound and/or CT. RESULTS: Eleven patients received intra-operative cryosurgery and 27 received percutaneous cryosurgery. Fourteen patients underwent two procedures of cryosurgery and three underwent three procedures of cryosurgery. (125)Iodine seed implantation was performed during the freezing procedure in 29 patients and within 3-7 days after cryosurgery in nine patients under ultrasound and CT guidance. Fifteen patients, of whom 13 had metastases of peripancreatic lymph nodes or liver received regional chemotherapy. At 3 months after therapy, a CT follow-up was performed to estimate the tumor response to therapy. Most of the patients had varying degrees of tumor necrosis. A complete response of the tumor was seen in 23.6% of patients, a partial response in 42.1%, stable disease in 26.3% and progressive disease in 7.9%. The adverse effects associated with cryosurgery mainly included pain of the upper abdomen and increased serum amylase activity. Acute pancreatitis was seen in five patients, one of whom presented a severe type of pancreatitis. During the followed-up of a median of 16 months (range of 5-37) median overall survival was 12 months, 19 patients (50.0%) survived for 12 months or longer and four survived for 24 months or longer. CONCLUSION: As it is far less invasive than conventional pancreas resection and entails a low rate of adverse effects, cryosurgery should be the choice modality for most patients with locally advanced pancreatic cancer. (125)Iodine seed implantation can destroy residue survival cancer cells after cryosurgery. Hence, combination of both modalities has a complementary effect.     

Cryosurgery as treatment modality for colorectal liver metastases

Liver metastases occur in more than 40% of the patients with colorectal cancer. The best prospect of cure is achieved by resection of the metastases. Only 10-15% of the patients with colorectal metastases are candidates for resection. When resection is impossible, other treatment options are limited. Response rates to chemotherapy are around 40%, but survival benefit is generally limited to a few months. Recently, cryosurgery has provided a new therapeutic approach for unresectable colorectal liver metastases. The metastases are localized by ultrasonography and are subsequently frozen with the aid of cryosurgical equipment. The treatment results in necrosis of the tumor and is characterized by low mortality and acceptable morbidity. Experience with cryosurgery is limited, but the results are promising. Various studies report a 1-year survival of more than 70% and a 2-year survival of > 50%. Disease-free survival after 2 years varies between 20-29%. Recurrences in the liver are usually other lesions than those treated with cryosurgery. Cryosurgery in combination with resection or as sole treatment, can result in radical treatment for patients formerly considered unresectable. Resection of liver metastases, however, remains the gold standard in the treatment of liver metastases. The main indication for cryosurgery may be as a complement to hepatic resection in those patients in whom liver resection can not achieve complete tumor clearance.     

经皮经肝曲张血管栓塞术治疗门体分流性脑病疗效分析

目的探讨经皮经肝TH胶栓塞治疗分流性脑病的临床疗效。方法经皮经肝门静脉穿刺插管,治疗12例反复发作的肝性脑病患者,将TH胶注射到门、体分流道内,使其永久闭塞。术后随访观察疗效。结果成功率100%（12/12）。术后门体压力梯度由（21.9±1.8）mm Hg升至（26.3±3.2）mm Hg,差异有统计学意义（P=0.00）。发热和腹痛是常见的并发症,发生率分别为50.0%（6/12）和41.7%（5/12）;16.7%（2/12）患者出现可控制的腹水,未出现肝脏穿刺道出血、异位栓塞等严重并发症,无围手术期死亡病例。患者随访6～37个月,平均随访时间（22.7±9.8）个月。所有患者肝性脑病症状都明显好转。在随访期间有25.0%（3/12）患者肝性脑病复发,16.7%（2/12）患者出现上消化道出血,原因分别为食管静脉曲张破裂出血和门静脉高压性胃病出血,死亡2人（16.7%）,死亡原因分别为肝功能衰竭和肝癌。结论经皮经肝曲张血管栓塞术在复发性分流性脑病的治疗中显示出了可靠的疗效和良好的安全性,值得推广研究。     

肝癌的冷冻治疗

冷冻疗法己成为治疗不能手术切除肝癌的重要手段。冷冻方法可选择手术中冷冻，切除或不切除肿瘤、腹腔镜下冷冻，或在超声、CT下，经皮冷冻。作为一局部治疗，冷冻具有超越其他治疗方法的若干优点：仅消融肝内肿瘤组织，而少伤及正常组织；由于大血管流动血流的温热作用，冷冻可安全地治疗临近大血管的肝肿瘤；冷冻比手术更适宜治疗肝多发性肿瘤。冷冻联合肝动脉化疗栓塞（TACE）、酒精注射或^125碘粒子植入，有相辅相成的作用。对于冷冻在肝癌治疗中应用，可归结如下：①〈5cm，尤其〈3cm的肝癌，数目不超过3个，可以手术中冷冻或经皮冷冻。②〉5cm的肝癌，先作TACE，再给予经皮冷冻。③〉5cm，边缘不整，预计冷冻不完全的肝癌，可予手术中或经皮冷冻，同时在冷冻区周边部注射酒精或植入^125碘粒子。     

手术切除联合射频消融治疗结肠癌肝转移疗效分析

目的 探讨手术联合射频消融治疗结肠癌肝转移患者的治疗效果。方法 对2008年1月至2014年3月我科诊治的结肠癌肝转移接受结肠癌根治术和肝内肿瘤灶切除治疗的17例和结肠癌根治术后对肝内肿瘤行射频消融（RFA）治疗的12例患者的临床资料进行回顾性分析。绘制Kaplan-Meier生存曲线,进行生存分析。结果 单纯手术治疗的17例患者均于术后20个月内死亡,平均生存时间为（13.412±0.912）月,而手术联合射频消融治疗的12例患者随访6~28个月,平均生存时间为（18.496±2.139）月（P<0.05）;RFA治疗后患者均出现不同程度的恶心、呕吐、胸闷、右上腹痛、发热,血清ALT和AST轻度升高。结论 手术联合射频消融治疗结肠癌肝转移是一种可行的、安全的、有效的方法,可以明显延长患者的生存期。     

钙化积分与冠状动脉多支病变介入术后预后的相关性

目的 研究冠状动脉钙化积分（CCS）与冠状动脉多支血管病变患者经皮冠状动脉介入治疗（PCI）后近、远期预后的关系.方法 入选145例冠状动脉多支血管病变的冠心病患者,在PCI治疗前均接受了多排螺旋CT （MDCT）检查并计算CCS.根据CCS水平将患者分为三组：CCS≤100、CCS=101～400和CCS＞400组.记录患者PCI操作相关并发症,随访记录患者PCI术后主要不良心血管事件（MACE）情况.结果 CCS＞400组患者Syntax积分[（23.5＆#177;8.8）比（17.9＆#177;8.5）,P＜0.001]、三支血管病变的比率（75.4％比56.3％,P=0.015）和PCI操作相关并发症发生率（21.5％比5.0％,P=0.005）均显著高于CCS≤400组患者.所有患者随访360～2542 d（中位数952 d）,Kaplan-Meier生存分析显示CCS≤100、CCS=101～400和CCS＞400组患者累积无事件生存率差异无统计学意义（84.6％比78.0％比64.6％,P=0.141）.但女性患者中累积无事件生存率差异有统计学意义（100.0％比75.0％比50.0％,Log rank 6.836,P=0.033）.结论 在冠状动脉多支血管病变患者中CCS与PCI预后有关,CCS＞400提示较高的PCI并发症发生率.女性患者CCS越高PCI预后越差.     

Resection of localized recurrences after hepatectomy of colorectal cancer metastases

BACKGROUND/AIMS: Hepatectomy is generally considered the only mode of curative treatment available for patients with colorectal liver metastases, even though recurrence occurs in more than 60% of the patients. METHODOLOGY: This is a retrospective study examining the survival of 11 patients undergoing surgical excision of recurrences gained from 46 patients undergoing initial hepatectomy for metastatic colorectal cancer. These 46 patients had curative hepatectomy and no extrahepatic metastasis. RESULTS: Cancer recurred in 29 of the 46 patients after a median follow-up time of 29.5 months (range 2-183 months), and 11 had curative resection of localized recurrences. In 6 patients, the liver was the only site of recurrence and 4 patients had isolated lung metastases. One patient had liver and lung metastases. There was no perioperative mortality. The median survival time and cumulative 5-year survival rate for 11 patients after the repeated resection were 28 months and 43.8%, respectively. These results were comparable to the survival for 46 patients after the initial hepatectomy, in which the median survival was 29.5 months and the 5-year survival rate was 49.0%. CONCLUSIONS: In appropriately selected patients with colorectal cancer, surgical excision of localized recurrences after hepatectomy may be effective in prolonging survival.     

Cryotherapy for liver metastases

Cryotherapy is undergoing a renaissance in the treatment of nonresectable liver tumors. In a prospective case control study we assessed the morbidity, mortality, and efficacy of hepatic cryotherapy for liver metastases. Between January 1996 and September 1999 a total of 54 cryosurgical procedures were performed on 49 patients (median age 66 years, 21 women) with liver metastases. Patient, tumor, and operative details were recorded prospectively. Liver metastases originated from colorectal cancer (n=37), gastric cancer (n=3), renal cell carcinoma (n=2), and other primaries (n=7). Median follow-up was 13 months (1–32). The median number of liver metastases was 3 (range 1–10) with a median diameter of 3.9 cm (range 1.5–11). Twenty-one patients (43%) had cryoablation only, and 28 (57%) had liver resection in combination with cryoablation. One patient (2%) died within 30 postoperative days. Another 13 patients (27%) developed reversible complications. In 19 of 25 patients (76%) with preoperatively elevated serum CEA and colorectal metastases it returned to the normal range postoperatively. Twenty-eight patients (57%) developed tumor recurrence, eight of which with involvement of the cryosite. Overall median survival patients was 23 months, and survival in patients with colorectal metastases was 29 months. Hepatic cryotherapy is associated with tolerable morbidity and mortality. Efficacy is demonstrated by tumor marker results. Survival data are promising; however, long-term results must be provided to allow comparison with other treatment modalities. Accepted: 14 April 2000     

Prognostic factors following liver resection for hepatic metastases from colorectal cancer

AIM: To determine the impact of prognostic factors on survival of patients with metastases from colorectal cancer that underwent liver resection. METHODS: The records of 28 patients that underwent liver resection for metastases from colorectal cancer between April 1992 and September 2001 were retrospectively analyzed. Thirty-eight resections were performed (more than one resection in eight patients and two patients underwent re-resections). The primary tumor was resected in all the patients. A screening protocol for liver metastases including clinical examinations every three months, ultrassonography and CEA level until 5 years of follow-up and after every 6 months, was applied. The prognostic factors analyzed regarding the impact on survival were: Dukes C stage of primary tumor, size of metastasis >5 cm, a disease-free interval from primary tumor to metastasis < 1 year, CEA level > 100 ng/mL, resection margins < 1 cm and extrahepatic disease. The Kaplan-Meier curves, log rank and Cox regression were used for the statistical analysis. RESULTS: Perioperative morbidity and mortality were 39.3% and 3.6%, respectively. The 5-year survival rate was 35%. The independent prognostic factors were: disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease. CONCLUSIONS: The liver resection for metastases from colorectal cancer is a safe procedure with more than 30% 5-year survival. Disease-free interval from primary tumor to metastasis < 1 year and extrahepatic disease were independent prognostic factors.